LifeMD, Inc. (LFMD) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals a mixed picture: increased losses and a decline in revenue, yet strong cash position and strategic partnerships with Novo and Lilly. The Q&A highlights promising insurance-supported programs and strategic shifts, but concerns about revenue guidance and unclear management responses persist. With no market cap data, the lack of strong catalysts and mixed financial indicators suggest a neutral stock price movement in the short term.
Key Financial Performance
Revenue $50.2 million, essentially flat versus the prior year period of $50.9 million. Reasons for flat growth include nearly all revenue derived from recurring subscriptions.
Active Subscribers 365,000 at quarter end, representing approximately 26% year-over-year growth. Reasons for growth include a planned step-up in patient acquisition spend and strong subscriber momentum.
Gross Margin 88%, expanded approximately 420 basis points year-over-year. Reasons for improvement include lower shipping and fulfillment costs and the scaling of in-house pharmacy fulfillment.
Gross Profit $44.2 million, up 3% from the year-ago period despite flat year-over-year revenue growth. Reasons for growth include improved gross margin.
Selling and Marketing Expenses $29.8 million, an increase of 34% year-over-year. Reasons for increase include strategic front-loaded patient acquisition investment designed to drive subscriber growth in subsequent quarters.
GAAP Net Loss $9.6 million or $0.20 per diluted share, compared to a net loss of $2.4 million or $0.06 per diluted share in the prior year period. Reasons for increased loss include higher selling and marketing expenses.
Stock-Based Compensation $1.4 million, down from $2.5 million in the prior year period. Reasons for decrease include a continued focus on aligning management with long-term goals.
Adjusted EBITDA Loss of approximately $4.5 million, compared to an adjusted EBITDA of approximately $3.7 million in the prior year period. Reasons for loss include increased marketing expenses and investments in growth initiatives.
Cash Balance $34.5 million at quarter end, with no debt and a $30 million undrawn revolving credit facility. Reasons for strong cash position include strategic financial management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Weight Management: Sign-ups increased approximately 120% sequentially from Q4. Customer acquisition costs improved 4%-5% sequentially in Q1. Ended the quarter with just under 100,000 weight management patients. The market is expanding with new oral GLP-1 therapies and next-generation drugs.
Women's Health: Subscriber count grew more than 7x from Q4 base. On therapy retention is tracking north of 80%. Plans to introduce 7 new compounded pharmacy products focused on hormone and bone health.
RexMD and Men's Health: Approximately 215,000 active patients. Growth across ED, sleep, and hair loss categories. ED medications grew more than 40% versus Q4. Expanding into personalized pharmacy products across sexual health, dermatology, pain management, and longevity.
Insurance and Medicare Infrastructure: Ended the quarter with approximately 112 million covered lives and expects to reach 230 million by the end of the month. Medicare GLP-1 bridge launching July 1 to expand access for Medicare patients.
Pharmaceutical Partnerships: Strong momentum with pharmaceutical partners as the industry shifts toward direct-to-patient models. GLP-1 collaborations are a strong proof point.
AI Integration: AI is being deployed across clinical decision support, intake, documentation, patient support, revenue cycle, compliance, and back-office workflows. Expected to increase provider capacity and improve operational efficiency.
Pharmacy Operations: Affiliated pharmacy processes approximately 20,000 prescriptions per month. Operates a 22,500 square foot facility licensed in all 50 states. Significant capacity to expand offerings.
Platform Expansion: LifeMD is transitioning from a telehealth company to a comprehensive virtual healthcare platform. Focus on integrating care, medications, labs, insurance-supported services, and clinical support into one connected experience.
Revenue and Profitability Goals: Reaffirmed full-year guidance of $220-$230 million in revenue and $12-$17 million in adjusted EBITDA. Expects annualized run rate revenue above $250 million and adjusted EBITDA above $25 million by Q4 2026.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Customer Acquisition Costs: The company experienced a 34% year-over-year increase in selling and marketing expenses, reflecting a strategic front-loaded patient acquisition investment. This could pose a financial risk if the expected subscriber growth does not materialize as planned.
Adjusted EBITDA Loss: The company reported an adjusted EBITDA loss of $4.5 million for Q1 2026, compared to a loss of $3.7 million in the prior year period. This indicates ongoing financial challenges in achieving profitability.
Net Loss: LifeMD reported a GAAP net loss of $9.6 million for Q1 2026, significantly higher than the $2.4 million loss in the prior year period. This raises concerns about the company's ability to manage costs effectively.
Dependence on GLP-1 Therapy Market: The company is heavily reliant on the GLP-1 therapy market, which is dynamic and competitive. Any delays in the introduction of new therapies or changes in market dynamics could adversely impact growth.
Scaling AI and Pharmacy Operations: While AI and pharmacy operations are seen as growth levers, their successful implementation is critical. Any delays or inefficiencies in scaling these operations could hinder margin expansion and operational efficiency.
Insurance and Medicare Infrastructure: The company is expanding its insurance and Medicare infrastructure, but any regulatory changes or delays in implementation could impact its ability to scale effectively.
Marketing Spend Normalization: The company plans to normalize marketing spend after a peak in Q1. If this normalization does not lead to the anticipated subscriber growth, it could negatively affect financial performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: Reaffirmed full-year revenue guidance of $220 million to $230 million, representing 13% to 19% year-over-year growth. Annualized run rate revenue is expected to exceed $250 million by Q4 2026.
Adjusted EBITDA Guidance: Reaffirmed full-year adjusted EBITDA guidance of $12 million to $17 million. Annualized run rate adjusted EBITDA is expected to exceed $25 million by Q4 2026.
Q2 2026 Projections: Revenue expected to be between $47 million to $50 million. Adjusted EBITDA projected between negative $2 million to positive $1 million.
Weight Management Growth: Significant growth expected in weight management, driven by the adoption of oral GLP-1 therapies and a pipeline of 40 GLP-1 therapies in development. Customer acquisition costs improved by 4%-5% sequentially in Q1 2026.
Women's Health Expansion: Plans to introduce 7 new compounded pharmacy products focused on hormone and bone health in the coming months. Women's health program is scaling rapidly, with subscriber count growing more than 7x from Q4 2025.
AI Integration: AI tools expected to increase provider capacity and improve operational efficiency, with margin impact becoming more visible in the second half of 2026.
Pharmacy and Insurance Infrastructure: Pharmacy offerings expected to expand throughout 2026, with the affiliated pharmacy currently processing approximately 20,000 prescriptions per month. Insurance coverage expected to grow to approximately 230 million covered lives by the end of May 2026.
Medicare GLP-1 Bridge: Launching July 1, 2026, to expand access to GLP-1 therapies for Medicare patients at an affordable monthly cost.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you talk about your relationship with Novo and Lilly and how you are making money with them?
A:The relationships with Novo and Lilly are long-term collaborations. Discussions are ongoing about compliant ways to help more patients access therapies, and the company is optimistic about evolving these relationships in the next quarter or two. The company also expects to include next-generation therapies from these companies on its platform. Unit economics vary, with insurance-supported areas showing strong performance.
Q:What is the nature of the incremental marketing spend in Q1?
A:The elevated marketing spend in Q1 was productive, focusing on channels like Google Ads and social media. It allowed the company to acquire customers at historically attractive CPAs, increasing the active base by almost 13% and expanding the database of potential targets for future marketing.
Q:What are you seeing in terms of conversion rates, retention, and customer acquisition synergies from insurance-supported programs?
A:There is a considerable improvement in retention rates for insurance patients, with a significant reduction in customer acquisition costs (up to 50%). Retention has improved by at least 10 points over the first 3-6 months. Insurance patients pay lower membership fees but show optimal unit economics compared to self-pay patients.
Q:Why was there a year-over-year revenue decline despite coming in ahead of expectations?
A:The decline is due to a shift from compounded GLP-1 drugs to branded drugs, which have different unit economics. While revenue from branded drugs is lower, these patients have better retention, aligning with the company's long-term strategy.
Q:Can you provide more details on the second to third quarter EBITDA ramp and related initiatives?
A:The company is focusing on the insurance business, expanding to 147 additional plans, and improving platform economics. Marketing spend will decrease in the second half of the year, and cost efficiencies in SG&A, shipping, and fulfillment will contribute to EBITDA growth. Cross-care opportunities and technical improvements will also drive revenue.
Q:How does the CMS Bridge program extension through 2027 impact the company?
A:The extension is seen as a positive development, enabling Medicare beneficiaries to access GLP-1 medications. The company is working on strategies to leverage this opportunity, which could significantly impact the business in the second half of the year.
Q:What are your thoughts on the uptake of Foundayo compared to oral Wegovy?
A:The company declined to provide specific traction details for Foundayo versus oral Wegovy, citing collaboration agreements. However, it noted that Wegovy pill has more awareness and is slightly more popular on their platform.
Q:Why is Q2 revenue guidance not stronger despite strong demand for oral therapies?
A:The company is transitioning to quality revenue with a focus on retention and value. Insurance patients pay less, and the company is still optimizing RCM processes. The softness in Q2 revenue reflects this strategic shift.
Q:What is the outlook for weight management subscribers and the opportunity with self-insured employers?
A:The company expects consistent growth in weight management subscribers, with potential acceleration due to insurance offerings and the CMS Bridge program. The opportunity with self-insured employers is significant but currently deprioritized in favor of pharma and strategic partner collaborations.
Q:How does the FDA's proposal to exclude semaglutides from the bulk list impact the company?
A:The proposal has no impact on the business as the company does not compound these medications. The focus remains on helping patients access branded therapies.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details about the traction of Foundayo versus oral Wegovy, citing collaboration agreements. Additionally, they did not elaborate on the prescriber documentation framework for individualized medical necessity standards or discussions with the FDA.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI
Customer acquisition
ED
GLP therapy
GLPs
Justin
RexMD men
acquisition volume
addition history
balance sheet
base
capacity
care program
compounding
cost
country
efficiency
facility
fulfillment
group
house pharmacy
improvement
infrastructure
injectables
insurance coverage
lever
life
loss stockholder
margin expansion
patient day
pharmacy capability
pharmacy offering
pharmacy product
phase access
shareholder letter
shift
sleep
start
stockholder share
support
LFMD Transcript
LifeMD, Inc. (LFMD) Q1 2026 Earnings Call Transcript
Unknown5-6
The earnings call reveals a mixed picture: increased losses and a decline in revenue, yet strong cash position and strategic partnerships with Novo and Lilly. The Q&A highlights promising insurance-supported programs and strategic shifts, but concerns about revenue guidance and unclear management responses persist. With no market cap data, the lack of strong catalysts and mixed financial indicators suggest a neutral stock price movement in the short term.
LifeMD, Inc. (LFMD) Q4 2025 Earnings Call Transcript
Positive3-9
The earnings call highlights strong financial performance with revenue and EBITDA growth, no debt, and a positive cash position. The Q&A reveals robust demand for the Wegovy pill, promising initial retention rates, and strategic investments in growth areas like women's health. While management was vague on some specifics, the overall sentiment remains positive due to strong financial metrics, optimistic guidance, and strategic partnerships, despite some uncertainties.
LifeMD, Inc. (LFMD) Q3 2025 Earnings Call Transcript
Unknown11-17
The earnings call reveals several concerns: a decline in weight management revenue, reduced financial guidance, and margin pressures due to shifts in business mix. Although there is optimism for 2026 and some positive developments like insurance coverage and new product lines, these are long-term prospects. The immediate financial outlook is weakened by the revised guidance and margin erosion, leading to a likely negative market reaction in the short term.
LifeMD, Inc. (LFMD) Q2 2025 Earnings Call Transcript
Unknown8-5
The earnings call presents mixed signals: strong telehealth revenue growth and strategic partnerships are positive, but concerns arise from fluctuating customer acquisition costs and guidance reduction related to the RexMD business. The Q&A reveals management's evasiveness on certain metrics, which can create uncertainty. Despite positive new initiatives and raised guidance for 2025, the immediate impact is tempered by operational challenges and lack of clear answers on key metrics, resulting in a neutral sentiment.
LFMD Slides
LFMD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
